Propanc Biopharma, Inc.
PPCB· Nasdaq
PPCBPropanc Biopharma, Inc.
Filed Feb 14, 2020 · 10-Q · 45 days after period end · 0001493152-20-002576
| Metric | Q2 2020 | Q2 2019 | Q2 2018 | Q2 2017 |
|---|---|---|---|---|
| Net Income | -$1.87M | -$1.45M | -$2.20M | -$3.76M |
| EPS Diluted | -$1,250.78 | -$41.33 | -$0.20 | -$1.13 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Propanc Biopharma, Inc. · CIK 1517681 · Engraved from SEC EDGAR
ended Dec 31, 2019 · filed Feb 14, 2020 · 45 d after period end
